Australia's most trusted
source of pharma news
Saturday, 02 August 2025
Posted 1 August 2025 AM
More than $215 million has been knocked off future PBS earnings, as a deal between Arrotex and South Korea's Celltrion sees two blockbusters face biosimilar competition - one for the first time - while Sandoz takes aim at another blockbuster market.
The two franchises hit with the statutory 25 per cent price reduction from today have a combined PBS earnings of $874.5 million a year, leaving Johnson & Johnson and Amgen significantly lighter in the pocket.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.